Synergistic enhancement of cancer therapy using a combination of fusion protein MG7-scFv/SEB and tumor necrosis factor alpha.

The fusion protein MG7-scFv/SEB has shown anti-tumor activity on gastric cancer in vitro and in vivo. Tumor necrosis factor-alpha (TNF-α) is a cytokine exerting anti-tumor effectiveness in various models and modes of applications. In this study, we explored the combination effects of MG7-scFv/SEB and TNF-α in experimental gastric cancer. Both MG7-scFv/SEB and TNF-α could effectively result in a significant inhibition of tumor growth in our experimental models when administered alone. What’s more, MG7-scFv/SEB synergized with TNF-α in further reducing the growth of gastric tumors in gastric-tumor-bearing rats as compared to mono therapy. Additionally, the survival rate of gastric-tumorbearing rats administrated with combined therapy was significantly higher than that of rats treated with MG7-scFv/SEB or TNF-α. These results indicate that combined therapy with MG7-scFv/SEB and TNF-α is a promising strategy for human cancer therapy.